证券代码：002550 证券简称：千红制药 公告编号：2025-023 常州千红生化制药股份有限公司 关于与建元信托股份有限公司签署和解协议 暨诉讼进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 年年度报告》、《2020 年年度报告》 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）2018 年 购买了安信创赢 51 号·特定资产收益权集合资金信托计划（以下简称"创赢 51 号信托计划"）理财产品，到期时间为 2019 年 12 月 29 日。自 2019 年 12 月起， 该笔理财产品出现逾期未兑付，逾期本金 17,000 万元。公司就创赢 51 号信托计 划项下与建元信托股份有限公司（以下简称"建元信托"）的受益权转让协议纠 纷向上海金融法院提起诉讼，案号为（2020）沪 74 民初 3 号，法院受理时的涉 诉金额为 17,786.94 万元。具体情况详见公司披露的《2018 年年度报告》、 《2019 、《2021 年年度报告》、《2022 年年度报告》、 《2023 年年度报告》与《诉讼公告》（公告编号：2020-0 ...

证券代码：002550 证券简称：千红制药 公告编号：2025-023 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）2018 年 购买了安信创赢 51 号·特定资产收益权集合资金信托计划（以下简称"创赢 51 号信托计划"）理财产品，到期时间为 2019 年 12 月 29 日。自 2019 年 12 月起， 该笔理财产品出现逾期未兑付，逾期本金 17,000 万元。公司就创赢 51 号信托计 划项下与建元信托股份有限公司（以下简称"建元信托"）的受益权转让协议纠 纷向上海金融法院提起诉讼，案号为（2020）沪 74 民初 3 号，法院受理时的涉 诉金额为 17,786.94 万元。具体情况详见公司披露的《2018 年年度报告》、《2019 年年度报告》、《2020 年年度报告》、《2021 年年度报告》、《2022 年年度报告》、 《2023 年年度报告》与《诉讼公告》（公告编号：2020-001）。 二、本次诉讼事项的进展情况 2025年8月13日，经双方友好协商，公司与建元信托股份有限公司达成和解 1. 案件所处的诉讼阶段：1 宗案件已和解且已撤诉。 2. 上市公司所处的当事人地位：原告 ...

Group 1 - The company held its ninth meeting of the sixth board of directors on August 13, 2025, with all nine directors present, complying with legal and regulatory requirements [1] - The board approved a resolution regarding a settlement agreement with Jianyuan Trust Co., Ltd., with unanimous support from all directors [1] - The settlement agreement includes a payment of 56,994,275.53 yuan from Jianyuan Trust to the company, representing 50% of the remaining amount after deducting previously paid principal and returns [2]

第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002550 证券简称：千红制药 公告编号：2025-022 常州千红生化制药股份有限公司 （一）审议通过了《关于公司与建元信托股份有限公司签署和解协议的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票，议案获得通过。 2025 年 8 月 13 日，经双方友好协商，公司与建元信托股份有限公司就创赢 51 号信托计划理财产品纠纷案（案号（2020）沪 74 民初 3 号）达成和解并签署 了《和解协议》。该协议签署当日，建元信托向公司支付和解款 56,994,275.53 元， 即创赢 51 号信托计划项下投资本金金额 17,000 万元减去已兑付的信托资金本金 及信托收益共 56,011,448.94 元后的剩余部分的 50%；同时按照协议约定，公司 向上海金融法院就该案件提交撤诉申请，不可撤销地申请上海金融法院作出准予 其撤诉的裁定并将创赢 51 号信托计划项下 62,862,549.50 份信托受益权转让给建 元信托，转让完成后公司仍 ...

金融界消息 截至2025年8月13日收盘，千红制药（002550）报收于10.12元，上涨1.91%，换手率 7.18%，成交量68.74万手，成交金额6.87亿元。 资金流向方面，今日主力资金净流入1306.22万元，占比成交额1.9%。其中，超大单净流入895.59万 元、占成交额1.3%，大单净流入410.64万元、占成交额0.6%，中单净流出流出1021.29万元、占成交额 1.49%，小单净流出284.93万元、占成交额0.41%。 通过天眼查大数据分析，常州千红生化制药股份有限公司共对外投资了9家企业，参与招投标项目5000 次，知识产权方面有商标信息46条，专利信息56条，此外企业还拥有行政许可182个。 来源：金融界 天眼查商业履历信息显示，常州千红生化制药股份有限公司，成立于2003年，位于常州市，是一家以从 事医药制造业为主的企业。企业注册资本127980万人民币，实缴资本60172.5427万人民币。公司法定代 表人为王轲。 千红制药最新一期业绩显示，截至2025一季报，公司营业总收入4.51亿元、同比减少2.22%，归属净利 润1.61亿元，同比增长54.62%，扣非净利润1.07亿元 ...

Core Viewpoint - Qianhong Pharmaceutical (002550.SZ) is undergoing a strategic transformation driven by innovation, yet its current performance is still heavily reliant on traditional biochemical drugs, with innovative drugs not yet contributing to revenue growth. Despite a significant increase in stock price, the company's revenue has been declining, indicating a challenging financial environment [3][4][5]. Financial Performance - Qianhong Pharmaceutical's revenue has experienced a continuous decline over the past two years, with 2024 revenue projected to be lower than 2019 levels, specifically at 15.26 billion yuan, down from a peak of 23.04 billion yuan in 2022 [6][7]. - The company's two main product lines, the formulation series and raw material series, have seen significant revenue drops, with the formulation series down 3.18% to approximately 10.79 billion yuan and the raw material series down 35.93% to 4.43 billion yuan in 2024 [7]. - Despite the revenue decline, the net profit attributable to shareholders is expected to rise significantly to 3.56 billion yuan in 2024, a 95.77% increase year-on-year, driven by increased sales volume and improved gross margins [8][9]. Strategic Moves - Qianhong Pharmaceutical plans to invest 3.9 billion yuan to acquire the bankrupt Changzhou Fangyuan Pharmaceutical Co., focusing on its core product, Sulbactam, to seek new growth opportunities [4][5]. - The company aims to leverage its regional advantages and marketing capabilities to enhance the sales performance of Sulbactam post-acquisition [5]. Innovation and Future Prospects - The company is actively pursuing innovation in drug development, with plans to complete key clinical trials for two core new drugs, QHRD107 and QHRD106, by 2026 [11]. - QHRD106 has successfully progressed to phase III clinical trials, indicating potential future revenue streams from innovative products [11]. Shareholder Activity - Recent shareholder activities show a divergence in confidence, with the vice chairman and second-largest shareholder, Zhao Gang, reducing his stake by over 70 million yuan, while the actual controller, Wang Yaofang, has increased his holdings [12][13].

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

Core Insights - The precision medicine sector experienced a slight increase of 0.62% on August 7, with a net outflow of main capital amounting to 93.50 million yuan [1] - A total of 23 stocks within the sector saw gains, while another 23 stocks faced declines [1] Capital Flow Analysis - The companies with the highest net outflows were: - Qianhong Pharmaceutical: 187 million yuan - Saily Medical: 139 million yuan - Zhifei Biological: 134 million yuan - Betta Pharmaceuticals: 104 million yuan - Junshi Biosciences-U: 78.25 million yuan [1] Notable Stock Performances - The following companies showed significant net inflows: - Berry Genomics: 207 million yuan, with a price increase of 5.26% - Lide Man: 158 million yuan, with a price increase of 20.02% - Kehua Bio: 143 million yuan, with a price increase of 9.96% - Da'an Gene: 60.09 million yuan, with a price increase of 2.98% - Sanbo Brain Science: 57.30 million yuan, with a price increase of 5.12% [1]

Group 1 - Hewei Electric achieved a net profit of 243 million yuan in the first half of 2025, a year-on-year increase of 56.79% [1] - The company reported a revenue of 1.884 billion yuan, representing a year-on-year growth of 36.39% [1] - Hewei Electric specializes in the sales of wind power converters and photovoltaic inverters, along with related services [1] Group 2 - Jidian Co. received approval for a 1507.93 MW wind power project, increasing its approved project capacity to 1607.93 MW, over 10% of last year's total installed capacity [2] - The company focuses on the research, production, and sales of thermal power, hydropower, and renewable energy [2] Group 3 - Nanya New Materials reported a net profit of 87.19 million yuan in the first half of 2025, a year-on-year increase of 57.69% [2] - The company achieved a revenue of 2.305 billion yuan, reflecting a year-on-year growth of 43.06% [2] - Nanya specializes in the design, research, production, and sales of copper-clad laminates and bonding sheets [2] Group 4 - Rongzhi Rixin reported a net profit of 14.24 million yuan in the first half of 2025, a significant year-on-year increase of 2063.42% [2] - The company achieved a revenue of 256 million yuan, representing a year-on-year growth of 16.55% [2] - Rongzhi Rixin provides intelligent operation and maintenance solutions for industrial equipment [3] Group 5 - Jiasheng Group reported a net profit of 142 million yuan in the first half of 2025, a year-on-year decrease of 14.46% [4] - The company achieved a revenue of 1.171 billion yuan, showing a slight year-on-year growth of 0.19% [4] - Jiasheng specializes in the production and manufacturing of knitted sportswear [4] Group 6 - Lidong Group's subsidiary received project approvals for aluminum alloy wheels from international automotive manufacturers, with expected sales of approximately 1.643 billion yuan over the project duration [5][6] - The company focuses on the research, manufacturing, and sales of aluminum alloys and related products [6] Group 7 - Jianglong Shipbuilding won a bid for a 78.55 million yuan infrastructure project in the marine economic development zone [7] - The project has a duration of 540 days and involves the design, research, production, and sales of various types of boats [7] Group 8 - Liyuan Information reported a net profit of 96.13 million yuan in the first half of 2025, a year-on-year increase of 65.79% [31] - The company achieved a revenue of 4.034 billion yuan, reflecting a year-on-year growth of 17.46% [31] - Liyuan specializes in the distribution of electronic components and the development of smart grid products [31] Group 9 - Baijie Shenzhou reported a net profit of 450 million yuan in the first half of 2025, reversing a loss of 287.7 million yuan from the previous year [32] - The company achieved total revenue of 17.518 billion yuan, a year-on-year increase of 46% [32] - Baijie Shenzhou focuses on the research, development, production, and commercialization of innovative drugs [32] Group 10 - Xianhe Co. plans to invest 11 billion yuan in a new integrated high-performance paper-based material project [34] - The project will include the construction of production lines for bamboo pulp and high-performance paper-based materials [34] Group 11 - Zhongchuan Technology's subsidiary plans to invest approximately 5.712 billion yuan in a 1.3 million kilowatt wind power project [35] - The company specializes in wind turbine manufacturing and related engineering services [35] Group 12 - Source Technology received a purchase order worth 1.415 billion yuan for high-power laser chips [20] - The company focuses on the research, design, production, and sales of optical chips [21]

截至8月7日收盘，仿制药一致性评价概念下跌1.34%，位居概念板块跌幅榜前列，板块内，千红制药跌 停，华海药业、亚太药业、联环药业等跌幅居前，股价上涨的有18只，涨幅居前的有润都股份、海辰药 业、*ST苏吴等，分别上涨9.98%、7.22%、4.63%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | ...